Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies-Reference-Cited by-同舟云学术

Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies

Published:2014-12-11 Issue:1 Volume:169 Page:90-102
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Schuster Friedhelm R.¹,Stanglmaier Michael²,Woessmann Wilhelm³,Winkler Beate⁴,Siepermann Meinolf¹,Meisel Roland¹,Schlegel Paul G.⁴,Hess Jürgen⁵,Lindhofer Horst²⁵,Borkhardt Arndt¹,Buhmann Raymund⁶⁷

Affiliation:

1. Department of Paediatric Oncology; Haematology and Immunology; University of Duesseldorf; Duesseldorf Germany

2. TRION Research GmbH; Martinsried Germany

3. Department of Paediatric Haematology and Oncology; Justus-Liebig University; Giessen Germany

4. Department of Paediatric Haematology; Oncology and Stem cell Transplantation; University of Wuerzburg; Wuerzburg Germany

5. TRION Pharma GmbH; Munich

6. Department of Medicine III and Transfusion Medicine; University Hospital Grosshadern; LMU; Munich Germany

7. Helmholtz Zentrum Munich; German Research Centre for Environmental Health; Munich Germany

Funder

Bavarian Immunotherapy Network (BayImmuNet; STMWFK)

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13242/fullpdf

Reference37 articles.

1. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia;Anoop;Leukemia & Lymphoma,2012

2. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting;Atanackovic;Human Vaccines & Immunotherapeutics,2013

3. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols;Atra;British Journal of Haematology,2001

4. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group;Attarbaschi;Pediatric Blood & Cancer,2005

5. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion;Buhmann;Bone Marrow Transplantation,2009

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational and Experimental Evaluation of Linker Peptides and Thioredoxin Fusion Tag in CD20-rituximab Specific Interactions;Iranian Journal of Pharmaceutical Research;2023-02-15

2. Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry;RSC Chemical Biology;2022

3. Biology and Clinical Evaluation of T/NK Cell Engagers;Cancer Drug Discovery and Development;2022

4. Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges;Advanced Materials;2021-09-29

5. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma;Journal for ImmunoTherapy of Cancer;2021-07